Apogee Therapeutics secured up to $1.3 billion [1] in flexible financing from Blackstone Life Sciences on Wednesday to develop an eczema drug.
This partnership provides the clinical-stage biotechnology company with the capital necessary to move its lead candidate into final-stage testing and prepare for a commercial launch. The funding allows the company to pursue large-scale development without immediately diluting existing shareholder equity.
The financing package includes up to $800 million [2] in synthetic royalties and provides access to up to $500 million [2] in additional capital. These funds are earmarked for the phase-3 development and commercialization of zumilokibart, an anti-IL-13 antibody designed to treat moderate-to-severe atopic dermatitis [3, 4].
The agreement follows positive phase-2 trial data for zumilokibart in patients with moderate-to-severe atopic dermatitis [5]. By securing this non-dilutive funding, Apogee can advance its clinical pipeline while mitigating the financial risks associated with the costly phase-3 trial process.
Market reaction to the announcement on Wednesday was mixed. Some reports said that shares of Apogee Therapeutics, which trades on the NASDAQ under the ticker APOG, climbed approximately 16 percent [6] in pre-market trading. However, other reports said that shares fell in early trading following the announcement [7].
Blackstone Life Sciences, the investment arm of Blackstone Inc., will provide the strategic financing to support the drug's path to market [1, 3].
“Apogee Therapeutics secured up to $1.3 billion in flexible financing from Blackstone Life Sciences”
The deal highlights a growing trend of biotechnology companies utilizing synthetic royalties to fund expensive late-stage clinical trials. By partnering with a massive investment firm like Blackstone, Apogee gains the financial runway to compete in the crowded atopic dermatitis market without the immediate need for a secondary stock offering, which often lowers share prices.
